Teva Pharmaceutical Industries Dividends and Buybacks
Dividend criteria checks 0/6
Teva Pharmaceutical Industries does not currently pay a dividend.
Key information
0%
Dividend yield
n/a
Buyback Yield
Total Shareholder Yield | n/a |
Future Dividend Yield | 0% |
Dividend Growth | n/a |
Next dividend pay date | n/a |
Ex dividend date | n/a |
Dividend per share | US$0.340 |
Payout ratio | 0% |
Recent dividend and buyback updates
No updates
Recent updates
Teva: Becoming Increasingly Solid, But No Longer Undervalued
Dec 04Why Investors Shouldn't Be Surprised By Teva Pharmaceutical Industries Limited's (NYSE:TEVA) Low P/S
Nov 17Teva: Great Time To Buy Leading Generic Drugmaker With Growth Indicators And Lower Debt
Oct 23Is Teva Pharmaceutical Industries (NYSE:TEVA) Using Too Much Debt?
Oct 21Cheap Teva Stock Should Reward Patient Investors
Sep 09Teva's Transformation: From Generics Leader To Branded Drug Innovator
Aug 14Teva Pharmaceutical Industries Limited (NYSE:TEVA) Second-Quarter Results: Here's What Analysts Are Forecasting For This Year
Aug 02Teva's Q2 Outlook: Key Developments In Biosimilars And Pipeline Drugs
Jul 26Is Teva Pharmaceutical Industries (NYSE:TEVA) A Risky Investment?
Jul 12Teva Pharmaceutical: Buy This Bargain Before It's Gone
Jun 07Teva Pharmaceutical Industries Limited (NYSE:TEVA) Stock Catapults 27% Though Its Price And Business Still Lag The Industry
May 14Teva: Sustained Revenue Growth Amid Financial Strain (Rating Downgrade)
May 09Teva Pharmaceutical Industries (NYSE:TEVA) Has A Somewhat Strained Balance Sheet
Mar 26Teva Pharmaceutical Industries: Potential Outweighs Concerns
Mar 25Teva And Alvotech: Simlandi Approval Opens New Generic Market Opportunities
Feb 26A Review Of Teva's Prospects
Feb 15Teva Pharmaceutical Industries Limited's (NYSE:TEVA) Business And Shares Still Trailing The Industry
Jan 07Teva: 4 Key Drivers For A 2024 Revival (Upgraded Rating)
Dec 08Teva: Deeply Undervalued FCF Machine
Nov 20Teva: Focus On Innovation And Growth Means The Times They Are A Changing
Sep 14The Mighty Teva Pharmaceutical: Unveiling A Bullish Scenario You Must Consider
Aug 26Teva Q2 Earnings: Austedo And Anda Growth Impress, But Challenges Remain
Aug 02Teva Pharmaceutical: Lacking Capabilities For Strategic Investments
Jul 20Teva Pharmaceutical: New Growth Plan Could Restore Investor Confidence
Jun 15What To Expect From Teva Pharmaceutical In 2023 With A New CEO
Feb 15Can Teva Pharmaceutical's Q4 results bring positive surprise?
Feb 07Teva Pharmaceutical: Stuck In A Cycle Of Hope And Disappointment
Jan 19Tamiflu supplies released from national stockpile as nationwide shortage persists
Jan 12Teva Pharmaceutical: 2023 Could Finally Be The Stock's Breakout Year
Dec 28Federal appeals court temporarily blocks generics of Vanda's Hetlioz by Teva, Apotex
Dec 16Boston jury orders Lilly to pay $176.5M to Teva in migraine drug patent suit
Nov 10Stability and Growth of Payments
Fetching dividends data
Stable Dividend: Insufficient data to determine if TEVA's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if TEVA's dividend payments have been increasing.
Dividend Yield vs Market
Teva Pharmaceutical Industries Dividend Yield vs Market |
---|
Segment | Dividend Yield |
---|---|
Company (TEVA) | 0% |
Market Bottom 25% (US) | 1.4% |
Market Top 25% (US) | 4.3% |
Industry Average (Pharmaceuticals) | 2.4% |
Analyst forecast (TEVA) (up to 3 years) | 0% |
Notable Dividend: Unable to evaluate TEVA's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate TEVA's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Earnings Payout to Shareholders
Earnings Coverage: TEVA is not paying a notable dividend for the US market.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as TEVA has not reported any payouts.